Tarrytown, New York, USA – April 21, 2026

In a significant breakthrough for autoimmune neurology, Regeneron Pharmaceuticals has reported positive Phase 3 results for its investigational therapy cemdisiran in patients with generalized myasthenia gravis (gMG), demonstrating rapid, deep, and sustained disease control with a convenient once-every-12-weeks dosing regimen. The findings, published in a leading medical journal and presented at a major neurology conference, highlight cemdisiran’s potential as a best-in-class siRNA therapy targeting complement-mediated diseases.

Rapid and Sustained Clinical Efficacy in gMG

The Phase 3 NIMBLE trial showed that patients treated with cemdisiran experienced clinically meaningful improvements within just two weeks, a key differentiator compared to existing therapies. These improvements were measured across both daily functional outcomes and muscle strength assessments, two critical indicators of disease severity in Generalized Myasthenia Gravis.

At 24 weeks, cemdisiran achieved a 4.5-point improvement in MG-ADL scores, significantly outperforming placebo, and met its primary endpoint with high statistical significance (p<0.001). Additionally, nearly 77% of patients achieved clinically meaningful improvement, reinforcing the therapy’s strong efficacy profile. The study also met its key secondary endpoint, showing significant gains in the Quantitative Myasthenia Gravis (QMG) score, further validating its therapeutic impact.

Importantly, the durability of response was maintained throughout the study period, with no evidence of waning efficacy between quarterly doses, positioning cemdisiran as a long-acting, low-burden treatment option.

Advertisement

cGxPJobs Banner

Innovative siRNA Mechanism Targeting Complement Pathway

Cemdisiran represents a next-generation small interfering RNA (siRNA) therapy designed to reduce circulating complement factor 5 (C5), a key driver of immune-mediated damage in gMG. By targeting the complement pathway, the therapy helps restore neuromuscular communication, reducing symptoms such as muscle weakness, fatigue, and impaired mobility.

This mechanism offers a novel therapeutic approach compared to traditional immunosuppressive therapies, which often come with significant side effects and inconsistent efficacy. Cemdisiran’s ability to provide targeted, durable suppression of disease activity highlights its potential to redefine treatment standards in complement-mediated disorders.

Moreover, cemdisiran is being evaluated both as a monotherapy and in combination with other complement inhibitors, expanding its applicability across multiple rare diseases beyond gMG.

Favorable Safety Profile and Regulatory Progress

The safety data from the NIMBLE trial demonstrated that cemdisiran was generally well tolerated, with most adverse events being mild to moderate in severity. Notably, infection rates were lower in the treatment group compared to placebo, and there were no treatment discontinuations due to adverse events during the primary study period.

Serious complications, including meningococcal infections—a known risk with complement inhibition—were not observed during the trial, further supporting its safety profile. Additionally, key clinical outcomes such as hospitalization rates and myasthenic crises were numerically lower in patients receiving cemdisiran.

Regeneron has already submitted a U.S. regulatory application for cemdisiran, with additional global filings planned in 2026. If approved, cemdisiran could become the first siRNA therapy for gMG, representing a major milestone in RNA-based therapeutics and expanding treatment options for patients with limited alternatives.

As the burden of autoimmune diseases continues to rise, cemdisiran’s success underscores the growing importance of precision medicine and RNA-based therapies, paving the way for next-generation biologics that combine efficacy, convenience, and safety in chronic disease management.

Source: Regeneron press release